

Tuberculosis Therapeutics: Market Research Report

<https://marketpublishers.com/r/TDE8DD789FDEN.html>

Date: April 2010

Pages: 366

Price: US\$ 3,450.00 (Single User License)

ID: TDE8DD789FDEN

Abstracts

This report analyzes the Global market for Tuberculosis Therapeutics in US\$ Million.

Annual estimates and forecasts are provided for the period 2006 through 2015.

The report profiles 37 companies including AstraZeneca, Bayer AG, Bristol-Myers Squibb Co., Eli Lilly and Company, GlaxoSmithKline Plc, Lupin Limited, Novartis AG, Ranbaxy Laboratories Limited, Rusan Pharma Ltd., Rx for Africa, Inc., Sanofi-Aventis SA, Summit Plc, Tibotec BVBA, Otsuka Pharmaceutical Co., Ltd., and Sequella, Inc.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.

Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations

Disclaimers

Data Interpretation & Reporting Level

Quantitative Techniques & Analytics

Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

Tuberculosis: A Reality Check

Evolutionary Battle Against the TB Bug Drives the Future of the Market

TB Prevalence Statistics: A Current Review

Table 1. Worldwide Prevalence of TB Cases (in 000s) by Region for the Year (2007)
(includes corresponding Graph/Chart)

Table 2. Worldwide Incidence of TB Cases (in 000s) by Region for the Year (2007)
(includes corresponding Graph/Chart)

Table 3. Worldwide TB Mortality (2009): Breakdown of Number of TB Deaths (in '000s)
by Region (includes corresponding Graph/Chart)

Effectiveness of Current TB Management Strategies

Table 4. Currently Established TB First-Line Drugs, & Fixed-Dose Combination Drugs

Table 5. Currently Established TB Second-Line Drugs

Renewed Interest in TB Drugs Development

A Peek into the Current Drug Development Pipeline

TB Drugs in Pipeline as of the Year 2008

The Importance of Public-Private Partnerships (PPP)

The Promise of New Therapeutic Advancements
Nano Drug Delivery Offers a Ray of Hope
What's The Need of the Hour?
Moving Research to Market...
Challenges in Drug Development
Antidotes
Recalibration of Drug Arsenal Against Resistant & HIV Co-Infected TB Cases
TB Research in Dire Need of Funding

Table 6. Global Tuberculosis R&D Investment for the years 2005 through 2008 (In US\$ Million) (includes corresponding Graph/Chart)

Table 7. Worldwide TB Drugs Market (2007): Percentage Share Breakdown of Funding by Donor (includes corresponding Graph/Chart)

Table 8. Worldwide TB R&D Funding (2008): Percentage Share Breakdown of Allocated Funds by Area of Research (includes corresponding Graph/Chart)

Table 9. Global Tuberculosis R&D Investment: Breakdown of R&D Sponsors for the year 2008 (In US\$ Million)

Table 10. Global Tuberculosis R&D Investment (2008): Percentage Share Breakdown of Funds by Donor Type (includes corresponding Graph/Chart)

Bottleneck in Logistics Need to be Ironed Out
Other Trends & Issues
The State of Research Funding Amidst the Recession...
Growth in Drug Resistant TB Cases Drive Second-Line Therapeutic Drugs Market
HIV Infections: A Major Catalyst in Global Increase of TB
Pharma Companies Called Upon to Focus on TB Drug Development
High Prevalence in Developing Countries offer a Strong Commercial Opportunity

Table 11. Prevalence of TB in High Burden Countries (2007): Percentage Share Breakdown of Prevalent Cases by Country (includes corresponding Graph/Chart)

Table 12. Burden of TB Worldwide (2007): Breakdown of Number of cases of TB Prevalence ('000s) by Country (includes corresponding Graph/Chart)

Table 13. Burden of TB in High Burden Countries (2007): Breakdown of Number of Deaths ('000s) by Country (includes corresponding Graph/Chart)

A Peek Into the Commitments Voiced by High Burden Countries
MDR-TB on the Rise in Dragon Land
What's the Chinese Government Doing About It?
Indonesia: Pledges Support to TB Drug Research
South Africa Publicizes Its Commitment
Other Statistical Findings

Table 14. Tuberculosis Prevalence in Japan: Breakdown of Notified Patients by Age Group for the year 2006 through 2008 (includes corresponding Graph/Chart)

Table 15. Tuberculosis Prevalence in Japan: Breakdown of Notified Patients by Gender for the year 2006 through 2008 (includes corresponding Graph/Chart)

Table 16. Tuberculosis Prevalence in Japan: Breakdown of Notified Patients by Prefecture/Designated City for the year 2008 (includes corresponding Graph/Chart)

2.DISEASE & TREATMENT OVERVIEW

Tuberculosis (TB): A Prevalent, Yet Neglected Disease

Latent TB Infection

Active TB Infection

A Peek Into the Bacteria Causing the Disease...

Types of Tuberculosis

Pulmonary Tuberculosis

Extra Pulmonary Tuberculosis

Diagnosis of TB

Prevention of TB

The Cure

The DOTS Program: A Review

TB Drugs

First line Drugs

Isoniazid

Mode of Action & Dosage

Side Effects

Rifampin

Mode of Action

Side Effects

Pyrazinamide

Dosage

Mode of Action

Side Effects

Ethambutol

Mode of Action

Side Effects

Streptomycin

Second Line Drugs

Aminoglycosides

Mode of Action

Fluoroquinolones

Moxifloxacin (MXF)

Cycloserine

p-aminosalicylic acid (PAS or P)

3.RECENT INDUSTRY ACTIVITY

Across America Financial Services Acquires Apro Bio Pharmaceutical

Academia Sinica Inks MoU with Infectious Disease Research Institute

TB Alliance Enters into Collaboration with Tibotec

Rx for Africa Inks Letter of Intent with Rusan Pharma

Johnson & Johnson to Establish Drug Research Centre

Anacor Inks Agreements with Two Non-profit Organizations

Lupin Obtains USFDA Approval

Sequella Commence Phase IB Study for SQ109

Regional Model TB Center Establishes New Center

AstraZeneca to Commence Safety Studies for TB Drug Candidate

GADD and TIM Enters into Partnership

NWHD to Establish New Tuberculosis Facility

Cadila Pharmaceuticals Launches Risorine

Merck and Eli Lilly Collaborate for TB Treatment

Sanofi-aventis Enters into Collaboration with TB Alliance

Summit Corp Enters into Co development Agreement with Lilly PPP

NITD Collaborates with TB Alliance to Discover New Anti-TB Drugs

Ranbaxy Enters into Alliance with DBT for TB Drug Discovery and Research

Sanofi pasteur Inks License and Research Agreement with SSI

4.FOCUS ON SELECT GLOBAL PLAYERS

Profiles of generic drug companies & pharma majors, developing TB drugs in collaboration with not-for profit organizations & academic institutes

AstraZeneca (UK)

Bayer AG (Germany)

Bristol-Myers Squibb Co. (USA)

Eli Lilly and Company (USA)

GlaxoSmithKline Plc. (UK)

Lupin Limited (India)

Novartis AG (Switzerland)

Ranbaxy Laboratories Limited (India)

Rusan Pharma Ltd., (India)

Rx for Africa, Inc., (USA)

Sanofi-Aventis SA (France)

Summit Plc (UK)

Tibotec BVBA (Belgium)

Otsuka Pharmaceutical Co., Ltd. (Japan)

Sequella, Inc., (USA)

Profiles of key non-profit organizations & academic institutes

Global Alliance for TB Drug Development (USA)

Research Project Pipeline of the Global Alliance for TB Drug Development As of the Year 2009

Institute of Microbiology, Chinese Academy of Sciences (China)

5.GLOBAL MARKET PERSPECTIVE

Table 17. World Recent Past, Current & Future Market Analysis for Tuberculosis (TB) Therapeutics Analyzed with Annual Sales in US\$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

III. COMPETITIVE LANDSCAPE

Total Companies Profiled: 37 (including Divisions/Subsidiaries - 41)

Region/CountryPlayers

The United States

Canada

Japan
Europe
France
Germany
The United Kingdom
Italy
Spain
Rest of Europe
Asia-Pacific (Excluding Japan)
Africa

I would like to order

Product name: Tuberculosis Therapeutics: Market Research Report

Product link: <https://marketpublishers.com/r/TDE8DD789FDEN.html>

Price: US\$ 3,450.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/TDE8DD789FDEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970